Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Jan;25(1):43-50.
doi: 10.3802/jgo.2014.25.1.43. Epub 2014 Jan 8.

Survival benefit of taxane plus platinum in recurrent ovarian cancer with non-clear cell, non-mucinous histology

Hiroaki Kajiyama  1 , Kiyosumi Shibata  1 , Mika Mizuno  1 , Tomokazu Umezu  1 , Shiro Suzuki  1 , Ryuichiro Sekiya  1 , Kaoru Niimi  1 , Hiroko Mitsui  1 , Eiko Yamamoto  1 , Michiyasu Kawai  2 , Tetsuro Nagasaka  3 , Fumitaka Kikkawa  1
Affiliations

Survival benefit of taxane plus platinum in recurrent ovarian cancer with non-clear cell, non-mucinous histology

Hiroaki Kajiyama et al. J Gynecol Oncol. 2014 Jan.

Abstract

Objective: This study was conducted to examine the effects of front-line chemotherapy on overall survival (OS) and postrecurrence survival (PRS) of patients with recurrent ovarian cancer, when stratifying the histologic type.

Methods: Five hundred and seventy-four patients with recurrent ovarian cancer with sufficient clinical information, including front-line chemotherapy, were analyzed. The pathologic slides were evaluated by central pathologic review. The patients were divided into two groups: group A (n=261), who underwent taxane plus platinum, and group B (n=313), who underwent conventional platinum-based chemotherapy without taxanes.

Results: The median age was 54 years (range, 14 to 89 years). Group A had significantly better median OS (45.0 months vs. 30.3 months, p<0.001) and PRS (23.0 months vs. 13.0 months, p<0.001) compared to group B. The OS and PRS were similar between the groups in patients with clear cell or mucinous histology. In contrast, among patients with non-clear cell, non-mucinous histologies, the OS and PRS of group A were significantly better than those of group B (OS, p<0.001; PRS, p<0.001). Multivariable analyses revealed that, among patients with non-clear cell, non-mucinous histologies, chemotherapy including taxane and platinum was an independent predictor of favorable survival outcomes. Conversely, in patients with clear cell or mucinous histology, taxane-including platinum-based combination chemotherapy did not improve the OS and PRS compared to a conventional platinum-based regimen which did not include taxanes.

Conclusion: Since the emergence of taxane plus platinum, the prognosis of patients with recurrent ovarian cancer has improved. However, we here demonstrate that this improvement is limited to patients with non-clear cell, non-mucinous histologies.

Keywords: Chemotherapy; Histologic type; Overall survival; Postrecurrence survival; Recurrent ovarian cancer.

PubMed Disclaimer

Conflict of interest statement

No potential conflict of interest relevant to this article was reported.

Figures

Fig. 1
Fig. 1
Kaplan-Meier estimated overall survival of all 574 patients with recurrent ovarian cancer according to the type of first-line chemotherapy. Group A, taxane plus platinum; Group B, conventional platinum-based.
Fig. 2
Fig. 2
Kaplan-Meier estimated postrecurrence survival of all 574 patients with recurrent ovarian cancer according to the type of first-line chemotherapy. Group A, taxane plus platinum; Group B, conventional platinum-based.
Fig. 3
Fig. 3
Kaplan-Meier estimated overall survival (A) and postrecurrence survival (B) of the patients with clear cell or mucinous histology according to the type of first-line chemotherapy. Group A, taxane plus platinum; Group B, conventional platinum-based.
Fig. 4
Fig. 4
Kaplan-Meier estimated overall survival (A) and postrecurrence survival (B) of patients with serous, endometrioid, and other histologies according to the type of first-line chemotherapy. Group A, taxane plus platinum; Group B, conventional platinum-based.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90. - PubMed
    1. Eisenkop SM, Friedman RL, Wang HJ. Complete cytoreductive surgery is feasible and maximizes survival in patients with advanced epithelial ovarian cancer: a prospective study. Gynecol Oncol. 1998;69:103–108. - PubMed
    1. Friedlander M, Butow P, Stockler M, Gainford C, Martyn J, Oza A, et al. Symptom control in patients with recurrent ovarian cancer: measuring the benefit of palliative chemotherapy in women with platinum refractory/resistant ovarian cancer. Int J Gynecol Cancer. 2009;19(Suppl 2):S44–S48. - PubMed
    1. Meier W, du Bois A, Reuss A, Kuhn W, Olbricht S, Gropp M, et al. Topotecan versus treosulfan, an alkylating agent, in patients with epithelial ovarian cancer and relapse within 12 months following 1st-line platinum/paclitaxel chemotherapy: a prospectively randomized phase III trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group (AGO-OVAR) Gynecol Oncol. 2009;114:199–205. - PubMed
    1. Hızlı D, Boran N, Yılmaz S, Turan T, Altınbaş SK, Celik B, et al. Best predictors of survival outcome after tertiary cytoreduction in patients with recurrent platinum-sensitive epithelial ovarian cancer. Eur J Obstet Gynecol Reprod Biol. 2012;163:71–75. - PubMed